Skip to main content
. 2022 May 7;129(7):925–944. doi: 10.1007/s00702-022-02504-6

Fig. 3.

Fig. 3

Utilization of subgroups of antipsychotic drugs (APD) depending on severity of major depressive disorder. Second-generation APD: X2(2,43,868) = 4605.1, p< 0.001, V= 0.23; moderate vs. severe: X2(1,38,278) = 249.4, p< 0.001, ϕ = 0.08; moderate vs. psychotic: X2(1,17,906) = 4110.3, p< 0.001, ϕ = 0.48; severe vs. psychotic: X2(1,31,552) = 3514.2, p< 0.001, ϕ = 0.33. High-potency (hp) first-generation APDs: overall: X2(2,43,868) = 612.3, p< 0.001, V= 0.08; moderate vs. severe: X2(1,38,278) = 17.7, p< 0.001, ϕ = 0.02; moderate vs. psychotic: X2(1,17,906) = 440.3, p< 0.001, ϕ = 0.16; severe vs. psychotic: X2(1,31,552) = 455.9, p< 0.001, ϕ = 0.12. Low-potency (lp) first-generation APDs: overall: X2(2,43,868) = 147.9, p< 0.001, V= 0.04; moderate vs. severe: X2(1,38,278) = 146.8, p< 0.001, ϕ = 0.06; moderate vs. psychotic: X2(1,17,906) = 26.4, p< 0.001, ϕ = 0.04; severe vs. psychotic: X2(1,31,552) = 13.0, p< 0.001, ϕ = 0.02